South Korea · Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 387.04 billion. The enterprise value is 445.89 billion.
| Market Cap | 387.04B |
| Enterprise Value | 445.89B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Bio Plus has 58.91 million shares outstanding. The number of shares has increased by 5.97% in one year.
| Current Share Class | 58.91M |
| Shares Outstanding | 58.91M |
| Shares Change (YoY) | +5.97% |
| Shares Change (QoQ) | +1.48% |
| Owned by Insiders (%) | 32.68% |
| Owned by Institutions (%) | 6.16% |
| Float | 39.33M |
Valuation Ratios
The trailing PE ratio is 27.23.
| PE Ratio | 27.23 |
| Forward PE | n/a |
| PS Ratio | 4.34 |
| PB Ratio | 2.26 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 17.84 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.28, with an EV/FCF ratio of -7.35.
| EV / Earnings | 27.51 |
| EV / Sales | 5.00 |
| EV / EBITDA | 14.28 |
| EV / EBIT | 16.22 |
| EV / FCF | -7.35 |
Financial Position
The company has a current ratio of 0.54, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.54 |
| Quick Ratio | 0.34 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.84 |
| Debt / FCF | -0.95 |
| Interest Coverage | 90.96 |
Financial Efficiency
Return on equity (ROE) is 12.84% and return on invested capital (ROIC) is 9.03%.
| Return on Equity (ROE) | 12.84% |
| Return on Assets (ROA) | 7.71% |
| Return on Invested Capital (ROIC) | 9.03% |
| Return on Capital Employed (ROCE) | 15.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.93 |
Taxes
| Income Tax | -1.51B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.33% in the last 52 weeks. The beta is 0.56, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +27.33% |
| 50-Day Moving Average | 6,599.40 |
| 200-Day Moving Average | 7,060.15 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 1,001,273 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 89.16 billion and earned 16.21 billion in profits. Earnings per share was 241.25.
| Revenue | 89.16B |
| Gross Profit | 58.98B |
| Operating Income | 27.70B |
| Pretax Income | 19.07B |
| Net Income | 16.21B |
| EBITDA | 31.45B |
| EBIT | 27.70B |
| Earnings Per Share (EPS) | 241.25 |
Balance Sheet
The company has 15.96 billion in cash and 57.81 billion in debt, giving a net cash position of -41.85 billion or -710.38 per share.
| Cash & Cash Equivalents | 15.96B |
| Total Debt | 57.81B |
| Net Cash | -41.85B |
| Net Cash Per Share | -710.38 |
| Equity (Book Value) | 171.36B |
| Book Value Per Share | 2,622.08 |
| Working Capital | -43.82B |
Cash Flow
In the last 12 months, operating cash flow was 21.69 billion and capital expenditures -82.35 billion, giving a free cash flow of -60.66 billion.
| Operating Cash Flow | 21.69B |
| Capital Expenditures | -82.35B |
| Free Cash Flow | -60.66B |
| FCF Per Share | -1,029.77 |
Margins
Gross margin is 66.15%, with operating and profit margins of 31.07% and 18.18%.
| Gross Margin | 66.15% |
| Operating Margin | 31.07% |
| Pretax Margin | 21.39% |
| Profit Margin | 18.18% |
| EBITDA Margin | 35.27% |
| EBIT Margin | 31.07% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.75%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.75% |
| Dividend Growth (YoY) | -28.57% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 17.99% |
| Buyback Yield | -5.97% |
| Shareholder Yield | -5.22% |
| Earnings Yield | 4.19% |
| FCF Yield | -15.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 3.16 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.16 |
| Piotroski F-Score | 7 |